검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Concurrent chemoradiation (Concurrent chemoradiation) NovoCure Ltd.·Extranodal NK/T-cell Lymphoma, Nas… ORR 47% |
|---|---|
Overview Program | Concurrent chemoradiation |
Overview Company | NovoCure Ltd. |
Overview Modality | CGT |
Overview Target | Extranodal NK/T-cell Lymphoma, Nasal Typ |
Overview Indication | Extranodal NK/T-cell Lymphoma, Nasal Type |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen |
MoA Biomarker | biomarkers that complement established staging and Epstein-Barr virus (EBV)-DNA assessment |
PK/PD Species | Mouse, disease free survival (DFS), overall survival (OS), and toxicity. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, disease free survival (DFS), overall survival (OS), and toxicity. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis (10 |
Clinical Primary efficacy | ORR 47% |
Clinical ORR | 47% |
Clinical PFS | 8 |
Clinical OS | 14 |
Clinical Result source | ClinicalTrials.gov NCT00288054 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Concurrent chemoradiation (Concurrent chemoradiation) NovoCure Ltd.·Extranodal NK/T-cell Lymphoma, Nas… ORR 47% |
|---|---|
Overview Program | Concurrent chemoradiation |
Overview Company | NovoCure Ltd. |
Overview Modality | CGT |
Overview Target | Extranodal NK/T-cell Lymphoma, Nasal Typ |
Overview Indication | Extranodal NK/T-cell Lymphoma, Nasal Type |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen |
MoA Biomarker | biomarkers that complement established staging and Epstein-Barr virus (EBV)-DNA assessment |
PK/PD Species | Mouse, disease free survival (DFS), overall survival (OS), and toxicity. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, disease free survival (DFS), overall survival (OS), and toxicity. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis (10 |
Clinical Primary efficacy | ORR 47% |
Clinical ORR | 47% |
Clinical PFS | 8 |
Clinical OS | 14 |
Clinical Result source | ClinicalTrials.gov NCT00288054 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교